US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Sanofi Winthrop Industrie

< Previous 1 2 3 4 Next >
News headline image
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s half-year financial report for 2026
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi evolves its Executive Committee to support its next strategic chapter
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Availability of the aide-mémoire for Q2 2026 results
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi Foundation opens new chapter centered on future generations
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi launches 2026 global employee stock purchase plan
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi successfully prices 2.3 billion of bond issue
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Q1 2026: double-digit sales and business EPS growth
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
From Sanofi Winthrop Industrie
Via GlobeNewswire
< Previous 1 2 3 4 Next >